Global pharma major Lupin intimated that it has secured a tentative approval from the US-based drug regulator, United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Azilsartan Medoxomil tablets.
The United States Food and Drug Administration (USFDA) has given approval for its Abbreviated New Drug Application (ANDA), Azilsartan Medoxomil tablets (in the strengths of 40 mg and 80 mg) to market a generic equivalent of Edarbi tablets (in the strengths of 40 mg and 80 mg) of Arbor Pharmaceuticals, LW.
The product will be manufactured at Lupin's Nagpur facility (Maharashtra) in India. As per IQVIA MAT September 2021 data, Azilsartan Medoxomil tablets (RLD: Edarbi tablets) had estimated annual sales of $103.4 million in the U.S.
The company reported a consolidated net loss of Rs 2,094.87 crore in Q2 FY22 as against net profit of Rs 213.51 crore in Q2 FY21. On a consolidated basis, net sales rose 5.9% to Rs 4,003.42 crore in Q2 FY22 over Q2 FY21.
Shares of Lupin shed 0.35% to Rs 909.05 on BSE. Lupin is an innovation-led transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU